Apollo Acquisition

Apollo Therapeutics is a biopharmaceutical company focused on translating fundamental medical research into innovative medicines through a unique hub-and-spoke portfolio model. Originally founded as a consortium between world-leading UK universities (Cambridge, Imperial College London, and UCL) and major pharmaceutical companies, it now operates as an independent entity with a broad pipeline of over 20 programs. The company identifies promising early-stage assets from its academic partners and advances them through clinical proof-of-concept, focusing on areas such as immunology, oncology, and rare diseases. Apollo's lead programs include camoteskimab, an anti-IL-18 antibody, and APL-9796, a monoclonal antibody targeting ZIP12 for pulmonary hypertension.